Poltreg S.A.

Warsaw Stock Exchange PTG.WA

Poltreg S.A. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -8.01 M

Poltreg S.A. Net Cash Used For Investing Activities is USD -8.01 M for the year ending December 31, 2023, a -594.76% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Poltreg S.A. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -1.15 M, a -926.07% change year over year.
Poltreg S.A. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -112.31 K, a -215.88% change year over year.
Poltreg S.A. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD 96.92 K, a -11.68% change year over year.
Poltreg S.A. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD 109.73 K, a -91.30% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Warsaw Stock Exchange: PTG.WA

Poltreg S.A.

CEO	Mr. Piotr Trzonkowsk
IPO Date	Nov. 23, 2021
Location	Poland
Headquarters	Waly Piastowskie 1 lok. 1508
Employees	25
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Key trends

Past 5 years